CStone Pharma, Shenwan Hongyuan seek HK listings

By Jonathan Breen
12 Nov 2018

China's CStone Pharmaceuticals is planning to float in Hong Kong, submitting a draft prospectus through sponsors Goldman Sachs and Morgan Stanley.

The clinical-stage biotechnology company, which is backed by a WuXi Apptec-linked fund, focuses on developing and commercialising immune-oncology (IO) and molecularly-targeted drugs for cancer treatment. Its top three IO drugs, PD-L1, PD-1 and CTLA-4, are at the clinical stage.

It also has various research and development contracts with ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial